Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Acquired by Jane Street Group LLC

Jane Street Group LLC lifted its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 102.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 323,638 shares of the biotechnology company's stock after purchasing an additional 164,006 shares during the period. Jane Street Group LLC owned about 0.20% of Ironwood Pharmaceuticals worth $1,333,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Armistice Capital LLC grew its stake in Ironwood Pharmaceuticals by 44.4% during the 2nd quarter. Armistice Capital LLC now owns 7,800,000 shares of the biotechnology company's stock valued at $50,856,000 after purchasing an additional 2,400,000 shares in the last quarter. Pacer Advisors Inc. grew its position in shares of Ironwood Pharmaceuticals by 26.6% during the third quarter. Pacer Advisors Inc. now owns 11,279,822 shares of the biotechnology company's stock worth $46,473,000 after buying an additional 2,372,183 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Ironwood Pharmaceuticals by 20.7% in the second quarter. Renaissance Technologies LLC now owns 8,571,898 shares of the biotechnology company's stock worth $55,889,000 after buying an additional 1,472,097 shares during the last quarter. Stonepine Capital Management LLC raised its holdings in Ironwood Pharmaceuticals by 1,982.8% in the third quarter. Stonepine Capital Management LLC now owns 1,000,000 shares of the biotechnology company's stock valued at $4,120,000 after acquiring an additional 951,988 shares in the last quarter. Finally, State Street Corp raised its holdings in Ironwood Pharmaceuticals by 7.3% in the third quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company's stock valued at $40,870,000 after acquiring an additional 677,024 shares in the last quarter.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CFO Sravan Kumar Emany sold 11,001 shares of the firm's stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $4.08, for a total value of $44,884.08. Following the sale, the chief financial officer now owns 309,572 shares in the company, valued at approximately $1,263,053.76. This trade represents a 3.43 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 12.90% of the stock is currently owned by company insiders.

Ironwood Pharmaceuticals Trading Down 3.1 %

NASDAQ IRWD traded down $0.14 during trading hours on Friday, reaching $4.45. The company's stock had a trading volume of 1,767,082 shares, compared to its average volume of 1,751,649. The business has a 50-day simple moving average of $3.99 and a 200 day simple moving average of $4.83. Ironwood Pharmaceuticals, Inc. has a 52 week low of $3.06 and a 52 week high of $15.70. The stock has a market cap of $712.13 million, a PE ratio of -148.33 and a beta of 0.41.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.07). The company had revenue of $91.60 million during the quarter, compared to the consensus estimate of $91.22 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The company's revenue for the quarter was down 19.4% on a year-over-year basis. During the same period last year, the business posted $0.12 EPS. As a group, equities analysts predict that Ironwood Pharmaceuticals, Inc. will post 0.08 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on IRWD shares. Leerink Partnrs raised shares of Ironwood Pharmaceuticals to a "hold" rating in a research report on Monday, September 9th. StockNews.com downgraded Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Tuesday, November 12th. Finally, Leerink Partners assumed coverage on Ironwood Pharmaceuticals in a research report on Monday, September 9th. They issued a "market perform" rating and a $5.00 target price for the company. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $10.40.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.